New Two-Drug attack tested against tough pancreatic cancer
NCT ID NCT06015659
Summary
This study is testing whether adding an experimental drug called ZN-c3 to an approved chemotherapy (gemcitabine) can help control advanced pancreatic cancer that has worsened after initial treatment. The main goal is to see if this combination can keep the cancer from growing for at least 6 months. The trial will also closely monitor side effects to understand the safety of this new approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.